SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending after reporting strong earnings and authorizing a significant share buyback, which has paradoxically seen its stock decline, igniting community debate over executive stock-based compensation and dilution concerns amidst optimism for its AI/AR Smartglasses innovation and competition from rivals like Meta.

GhostwareOS (GHOST) is the Full-Stack Privacy Layer of Solana — a next-generation AI-driven infrastructure for encrypted communication, anonymous identity management, and untraceable transactions. By combining advanced zero-knowledge protocols with autonomous AI routing, GhostwareOS allows users and developers to operate invisibly across Web3. It powers decentralized apps that demand true digital anonymity, scalable privacy, and zero metadata leakage — restoring control to users in an overexposed internet age.

Ghost

GHOST CRYPTO is trending as the community, undeterred by FUD, aggressively champions its role as Solana's privacy layer, citing recent integrations, partnerships for private payments, and an anticipated revenue-sharing model as catalysts for significant future gains.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Recent news of Luckin Coffee's new premium flagship store and a key competitor ending aggressive pricing are fueling optimism for increased margins and market dominance. The community is eagerly discussing a potential uplisting to address the stock's perceived deep undervaluation amidst rapid growth and international expansion.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is trending following its recent earnings, which saw an EPS beat but a revenue miss attributed to contract transitions and a government shutdown. This mixed report has led to some investors expressing disappointment, while others view the resulting dip as a buying opportunity, emphasizing the company's substantial $47.2 billion backlog and its pivotal role in key sectors like nuclear energy and space systems for long-term growth.

River is building a chain-abstraction stablecoin system that enables cross-chain collateral, yield, and liquidity—all without bridging.   Powered by the omni-CDP stablecoin satUSD, users can earn, leverage, and scale across different ecosystems natively.   River features the first omni-CDP module that allows users to collateralize assets on Chain A and mint stablecoin satUSD on Chain B—without bridging the assets.

River

RIVER is trending due to recent strategic funding and high-profile backing, alongside ongoing community debate about its innovative stablecoin abstraction system. While many anticipate significant gains fueled by low circulating supply and potential major exchange listings, others foresee a dump, citing concerns over potential token unlocks and supply dynamics.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is trending after its Q4 earnings report, where strong profitability and a strategic shift towards prudent risk management were met with a severe market sell-off due to conservative revenue guidance and prevailing fintech sector weakness. The community is sharply divided, with many calling the stock oversold and deeply undervalued while others express frustration over management's outlook and perceived manipulation.

Kyndryl Holdings, Inc. is a technology services company, which engages in the provision of infrastructure services. It operates through the following segments: United States, Japan, Principal Markets, and Strategic Markets. The Principal Markets segment represents the aggregation of operations in Australia, New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, the United Kingdom, and Ireland. The company was founded on December 4, 2020 and is headquartered in New York, NY.

Kyndryl Holdings Inc

Kyndryl Holdings is trending following the abrupt departures of its CFO and General Counsel amid an ongoing accounting review, an SEC investigation, and a lowered fiscal outlook, which has caused a significant stock plunge. The community is sharply divided, with some seeing an extreme overreaction and a buying opportunity, while others warn of severe accounting issues and potential fraud.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar is garnering attention following a significant equity financing deal that strengthens its balance sheet and liquidity, building on a record year for retail sales and the expansion of Polestar 4 deliveries. Investors are weighing this positive financial injection and sales growth in several key markets against persistent concerns about the EV maker's path to sustained profitability and intense sector competition.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

Lyft is trending as investors anticipate its upcoming earnings report, with widespread debate on whether it will mirror Uber's recent stock performance amid intensifying concerns and opportunities presented by autonomous vehicle advancements. Community discussions are active around its potential as an acquisition target and the impact of its international partnerships.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending following its announced partnership with Palantir for specialized AI data engineering and a prime federal contract with the U.S. Missile Defense Agency. The community is buzzing with anticipation for a potentially explosive Q4 earnings report, expecting significant growth from INOD's critical role in AI data training for government, defense, and sovereign AI initiatives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 3,527,843 shares, an...

New Strong Sell Stocks for January 27th

DRTS, MPC and NRXP have been added to the Zacks Rank #5 (Strong Sell) List on January 27th, 2026.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by Brokerages

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the six research firms that are currently covering the company...

NRx Pharmaceuticals (NASDAQ:NRXP) Given "Buy" Rating at BTIG Research

BTIG Research reaffirmed a "buy" rating and set a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday...

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

Why Did NRXP Stock Surge 21% Pre-Market Today?

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

Equity

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.


D. Boral Capital Reaffirms "Buy" Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a "buy" rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research report on Monday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from Analysts

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Short Interest Up 38.2% in December

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 1,744,957 shares, a...

NRx Pharmaceuticals (NASDAQ:NRXP) Given Buy Rating at HC Wainwright

HC Wainwright reiterated a "buy" rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Average Rating of "Moderate Buy" from Analysts

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) have received an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, Marketbeat...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

NRXP
NRX Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NRXP News

NRXPNRX Pharmaceuticals Inc